Company Filing History:
Years Active: 2008
Title: Mylvaganam Jeyakumar: Innovator in Glycolipid Storage Disorder Treatments
Introduction
Mylvaganam Jeyakumar is a notable inventor based in Oxford, GB. He has made significant contributions to the field of therapeutic compositions, particularly in the treatment of glycolipid storage-related disorders. His innovative approach has the potential to improve the lives of many affected by these conditions.
Latest Patents
Jeyakumar holds a patent for "Therapeutic compositions and methods of treating glycolipid storage related disorders." This patent describes a method for treating glycolipid storage-related disorders by administering a therapeutically effective amount of an inhibitor of glycolipid synthesis. This method can be combined with an agent that increases the rate of glycolipid degradation or with bone marrow transplantation. The inhibitors of glycolipid synthesis mentioned in his patent include N-butyldeoxynojirimycin (NB-DNJ), N-butyldeoxygalactonojirimycin (NB-DGJ), and N-nonyldeoxynojirimycin (NN-DNJ). The disorders addressed by this patent include Gaucher disease, Sandhoff's disease, Fabry's disease, Tay-Sach's disease, Niemann-Pick C storage disease, GM1 gangliosidosis, and other genetic disorders where neuronal glycolipid accumulation contributes to disease pathology. Jeyakumar has 1 patent to his name.
Career Highlights
Mylvaganam Jeyakumar is currently associated with Actelion Pharmaceuticals Ltd, where he continues to work on innovative solutions for complex medical conditions. His research and development efforts are focused on advancing therapeutic options for patients suffering from glycolipid storage disorders.
Collaborations
Throughout his career, Jeyakumar has collaborated with esteemed colleagues, including Raymond A Dwek and Terence D Butters. These collaborations have further enriched his research and contributed to the advancement of therapeutic methods in his field.
Conclusion
Mylvaganam Jeyakumar is a pioneering inventor whose work in therapeutic compositions for glycolipid storage-related disorders holds promise for many patients. His contributions to the field exemplify the impact of innovative research in medicine.